Photo by nci from unsplash
Proteosome inhibitors (PI) are standard therapies for relapsed and/or refractory multiple myeloma (RRMM). Carfilzomib (CAR), an irreversible PI, is associated with greater risk of cardiovascular adverse events (CVAE) compared to… Click to show full abstract
Proteosome inhibitors (PI) are standard therapies for relapsed and/or refractory multiple myeloma (RRMM). Carfilzomib (CAR), an irreversible PI, is associated with greater risk of cardiovascular adverse events (CVAE) compared to bortezomib (BOR), a reversible PI. Whether PIs induce changes in
Keywords:
relapsed refractory;
refractory multiple;
cardiac structure;
multiple myeloma;
structure function
Journal Title: Journal of the American College of Cardiology
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of the American College of Cardiology
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!